Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
- Resource Type
- Article
- Authors
- Vichinsky, Elliott; Bernaudin, Françoise; Forni, Gian Luca; Gardner, Renee; Hassell, Kathryn; Heeney, Matthew M.; Inusa, Baba; Kutlar, Abdullah; Lane, Peter; Mathias, Liesl; Porter, John; Tebbi, Cameron; Wilson, Felicia; Griffel, Louis; Deng, Wei; Giannone, Vanessa; Coates, Thomas
- Source
- British Journal of Haematology. Aug2011, Vol. 154 Issue 3, p387-397. 11p. 4 Charts, 4 Graphs.
- Subject
- *DEFERASIROX
*SICKLE cell anemia
*IRON chelates
*CHELATION therapy
*DEFEROXAMINE
*DRUG side effects
*DIARRHEA
*CREATININE
*PATIENTS
- Language
- ISSN
- 0007-1048
Summary [ABSTRACT FROM AUTHOR]